News | December 13, 2023
Pfizer receives regulatory approvals to complete the acquisition of Seagen
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
Proposed combination enhances Pfizer’s position as a leading company in oncology
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Subscribe To Our Newsletter & Stay Updated
